The Dual Diverse Dynamic Reversible Effects of Ankaferd Blood Stopper on EPCR and PAI-1 Inside Vascular Endothelial Cells With and Without LPS Challenge

Lipopolisakkarit Varlığı ve Yokluğuğunda Vasküler Endotelyal Hücrelerde Endotelyal Protein C Reseptörü ve Plazminojen Aktivatör İnhibitör-1 Üzerinde Ankaferd’in Geri Dönüşümlü İkili Karşıt Etkileri

Afife Karabıyık¹, Erkan Yılmaz¹, Şükrü Güleç¹, İbrahim Haznedaroğlu², Nejat Akar¹

¹Ankara University, Department of Pediatric Molecular Genetics, Ankara, Turkey
²Hacettepe University, Department of Hematology, Ankara, Turkey

Abstract

Objective: Ankaferd blood stopper (ABS) is comprised of a mixture of the plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica. ABS is used as a topical hemostatic agent due to its anti-hemorrhagic effect, yet its hemostatic mechanism of action remains to be investigated. ABS does not affect the levels of coagulation factors II, V, VII, VIII, IX, X, XI and XII. The aim of this study was to investigate the effects of ABS on endothelium and immune response. As such, we evaluated changes in endothelial cell protein C receptor (EPCR) and plasminogen activator inhibitor type-1 (PAI-1) expression inside human umbilical vein endothelial cells (HUVECs) in the presence and absence of lipopolysaccharides (LPSs).

Material and Methods: We exposed HUVECs to 10 μL and 100 μL of ABS for 5 min, 25 min, 50 min, 6 h, and 24 h. Additionally, 10 μg mL⁻¹ of LPS was administered for 1 h to observe the effects of LPS challenge on HUVECs, and then the cells were treated with ABS for 5 min, 25 min, 50 min, and 6 h to observe the effects of ABS on HUVECs. Total RNA was isolated from HUVECs and then the level of expression of EPCR and PAI-1 mRNA was measured.

Results: Cells were microscopically observed to arise from the surface and adhere to each other following the administration of ABS to HUVECs. Additionally, after 24 h the cells had normal growth and physiology, which suggests that the adhesive cellular effects of ABS might be reversible. ABS had a negative effect on EPCR and PAI-1 expression; the effect in response to 100 μL was greater than that to 10 μL. EPCR and PAI-1 expression increased over time in response to LPS and 10 μL of ABS. EPCR and PAI-1 expression was very low during the first hour of exposure to LPS and 100 μL of ABS, but after 6 h increased to levels similar to those observed in response to LPS and 10 μL of ABS.

Conclusion: It was observed that ABS had dual diverse dynamic reversible effects on EPCR and PAI-1 expression in HUVECs, which were dependent on dose and concentration. ABS might play a role in numerous cellular mechanisms, in addition to having hemostatic effects.

Key Words: Ankaferd, EPCR, PAI-1, LPS, HUVEC
### Introduction

Ankaferd blood stopper (ABS) is a unique medicinal plant extract mixture, which has been historically used as a hemostatic agent in Turkish folk medicine [1,2]. ABS is comprised of a standardized mixture of the plants *Thymus vulgaris*, *Glycyrrhiza glabra*, *Vitis vinifera*, *Alpinia officinarum*, and *Urtica dioica*. Following numerous preclinical experiments [3-7] and a clinical phase I study [8], ABS was approved for use in Turkey as a medicinal product for the management of external hemorrhage, the post-dental surgery period, and bleeding refractory to conventional anti-hemorrhagic agents [9-16].

The basic mechanism of action of ABS is formation of an encapsulated protein network that provides focal attachment points for very rapid (<1 s) vital erythrocyte aggregation—known as the hemostatic ABS-web [1,17]. ABS-induced protein network formation with blood cells—particularly erythrocytes—covers the primary and secondary hemostatic system without disturbing individual coagulation factors [1,5,7,17]. ABS also has anti-infection and anti-neoplastic effects [18-20]. The distinct important molecular components of the ABS-induced hemostatic network involve vascular endothelium, proteins, and blood cells [17,21-24]. Endothelial protein C receptor (EPCR) plays a role in numerous hemostatic, vascular, and immunological actions [25-33]. Likewise, plasminogen activator inhibitor type-1 (PAI-1) is a very important biological mediator of fibrinolysis, infection, neoplasia, obesity, and wound healing [34-36].

The aim of the present study was to examine the intracellular effects of ABS on EPCR and PAI-1 expression in human umbilical vein endothelial cells (HUVECs), as these molecules may be novel administrators at the center of ABS-induced pleiotropic effects. Lipopolysaccharides (LPSs) are large molecules that act as toxins in order to observe immunological and hemostatic responses. Hence, the present study aimed to investigate the effects of ABS—with and without LPS challenge—on HUVECs, based on changes in EPCR and PAI-1 expression.

### Materials and Methods

ABS (10 μL and 100 μL) was administered to HUVECs (75 cm² and ~75% fullness) for 5 min, 25 min, 50 min, 6 h, and 24 h. Nuclei were isolated from HUVECs, and...
the level of expression of EPCR and PAI-1 was determined using a Roche LightCycler 1.5 (Basel, Switzerland). Fluorescence-marked primers were used to analyze EPCR and PAI-1 expression. Water with a pH of 2 (likely to be similar to the pH of ABS) was used as a control. In addition, to observe the effects of LPS challenge on HUVECs and those of ABS on HUVECs 10 μg mL⁻¹ of LPS (Sigma, Germany) was administered for 1 h to the test platform. Then, the cells were exposed to ABS for 5 min, 25 min, 50 min, and 6 h, so as to measure ABS-induced changes in EPCR and PAI-1 expression in relation to LPS. All experiments were repeated at least 2 times. Statistical analysis was based on two-way ANOVA with Bonferroni post test using GraphPad Prism v.5.0 (GraphPad Software, San Diego California, USA, http://www.graphpad.com).

Results

Cells were microscopically observed to arise from the plastic surface and adhere to each other in response to ABS administration to HUVECs. Additionally, after 24 h the cells had normal growth and physiology, which suggests that the adhesive cellular effects of ABS might be reversible. PAI-1 and EPCR expression was negatively affected by 24 h of exposure to 100 μL of ABS (Figures 1 and 2), but not by exposure to 10 μL of ABS. These findings indicate that the dose-dependent effects of ABS rely on PAI-1 and EPCR gene expression.

When LPS only was administered to HUVECs, EPCR and PAI-1 expression was higher than in HUVECs not exposed to LPS (data not shown). When LPS, and 10 μL and 100 μL of ABS were administered, the level of PAI-1 expression was stable and similar to that in the control after 6 h (Figure 3), whereas EPCR expression was very low during the first h of exposure, but increased after 6 h (Figure 4).

Figure 1: The effect of 10 μL and 100 μL of ABS on PAI-1 mRNA expression (*P < 0.05 and **P < 0.01). Error bars represent Means ± SD.

Figure 2: The effect of 10 μL and 100 μL of ABS on EPCR mRNA expression (**P < 0.01 and ***P < 0.001).

Figure 3: The effect of LPS, and 10 μL and 100 μL of ABS on PAI-1 mRNA expression. Error bars represent Means ± SD.

Figure 4: The effect of LPS, and 10 μL and 100 μL of ABS on EPCR mRNA expression (*P < 0.05 and ***P < 0.001). Error bars represent Means ± SD.
Discussion

ABS exhibited dual dynamic reversible effects on EPCR and PAI-1 expression in HUVECs. The observed immediate increase in the level of expression of pro-hemostatic PAI-1 and down-regulation of anti-coagulant EPCR following exposure to ABS are compatible with previous reports of ABS’s sudden anti-hemorrhagic effect [3-7] and clinical backgrounds [8-10, 13-15, 20]. The topical hemostatic efficacy of ABS has been previously tested in animals with normal [4,6] and dysfunctional hemostasis [5,7]. Experimental studies have led to the preclinical stage of this hemostatic product’s development. Short-term oral systemic administration of ABS in rabbits was reported to be hematologically and biochemically safe, as acute mucosal toxicity, hematotoxicity, hepatotoxicity, nephrotoxicity, and biochemical toxicity were not observed during the short-term follow-up [3]. Those preclinical results reflect a starting point to search any possible systemic confounding effect of ABS when applied to internal topical surfaces.

The use of ABS as a hemostatic agent for treating external hemorrhages and for dental treatment in humans is the first indication the ABS is safe and efficacious in humans [8]. A phase 1 double-blind, randomized cross-over placebo-controlled clinical study with a 5-d washout period between cross-over periods that included healthy volunteers reported that ABS was safe. Physiological cell-based coagulation was clinically obtained in response to topical ABS administered for the prevention and treatment of bleeding associated with many distinct clinicopathological states [8-10, 13-15, 20]. The ABS-induced hemostatic network consists of distinct important molecular components. Vital erythroid aggregation occurs in the spectrin, ankyrin, and actin proteins in red blood cell membranes. Essential erythroid proteins (ankyrin recurrent and FYVE bundle containing protein 1, spectrin alpha, actin-depolymerization factor, actin-depolymerizing factor, LIM bundle and actin-binding subunit 1 isoform a, LIM bundle and actin-binding subunit 1 isoform b, NADP-dependent malic enzyme, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, mitochondrial NADP [+] -dependent malic enzyme 3, ribulose bisphosphate carboxylase large chain, and maturease K) and the required ATP bioenergy (ATP synthase, ATP synthase beta subunit, ATP synthase alpha subunit, ATP-binding protein C12, TP synthase H+ transporter protein, ADF, and alpha-1,2-glycosyltransferase ALG10-A) are included in the ABS protein library. ABS also upregulates the GATA/FOG transcription system, affecting erythroid functions and urotensin II [21,23,24].

The initial vascular dynamic response to ABS is vasoconstriction, whereas the late response is vasodilatation [22]. The clinical control of critical bleeding states associated with deficiencies of either primary or secondary hemostasis has been previously examined [13, 38]. Patients with bleeding diathesis that could not be controlled with standard anti-hemorrhagic methods were successfully treated with topical ABS [9,13,16,38]. The present study’s results provide additional evidence that ABS might also affect vascular anticoagulant (namely EPCR) and antifibrinolytic (namely PAI-1) pathways in a balanced way to regulate hemostasis, even in individuals with clotting defects.

In addition to its hemostatic activity, ABS might also inhibit the growth of bacteria [19]. The anti-infection activity of ABS may bolster its current clinical use, as it inhibits the growth of bacteria in the region in which it is applied primarily for its hemostatic activity, such as infected wounds. The antimicrobial activity of ABS was tested against many pathogens, including A. baumannii, E. coli, K. pneumonia, P. aeruginosa, Enterobacter spp., Stenotrophomonas maltophilia, methicillin-resistant coagulase-negative Staphylococcus, vancomycin-susceptible Enterococcus, and VRE. ABS was reported to exhibit anti-bacterial activity against several gram-positive and gram-negative food and human pathogens [18]; however, the mechanism of action of ABS’s anti-infection effect is currently unknown. EPCR is an important molecule involved in the regulation of biological responses to severe infection [25,39]. LPS-induced endotoxemia requires the enzymatic active site of EPCR and PAR-1 [39]. In the present study ABS up-regulated the expression of EPCR and PAI-1 in the presence of LPS. The anti-infection effect of ABS might be related to its hemostatic effects on distinct steps of coagulation and vascular endothelium.

Preliminary observations indicated that ABS might have wound healing effects in different clinical states, such as oral infections, rectal ulcers, and neoplastic lesions [12,14,17]. PAI-1 is involved in tissue preservation and wound repair [34,35]. The overexpression of PAI-1 in response to ABS observed in the present study is an initial clue to set further experiments to search the importance of fibrinolysis regulators in the biological effects of ABS. PAI-1 is also involved in tumor responses [39-41]. In a case series topical ABS inhibited tumor angiogenesis [20], prothrombotic affect of PAI-1 in this respect shall also be further searched based on the observation in this study.

In conclusion, ABS exhibited dual de novo affects on EPCR and PAI-1 in HUVECs. HUVECs exposed to LPS challenge caused ABS-induced up-regulation of the expres-
sion of EPCR and PAI-1, indicating that ABS might act as a topical biological response modifier. As ABS is currently being developed in basic and clinical grounds, these novel observations indicate that additional research on the pleiotropic effects of this unique hemostatic agent is warranted.

Acknowledgement
None of the authors have any conflicts of interest related to the materials used or data presented herein. ABS was obtained from Ankaferd Drug Inc., Istanbul, Turkey.

References
1. Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, Firat HC. Haemostatic actions of the folkloric medicinal plant extract ankaferd blood stopper. J Int Med Res 2008;36:163-170.
2. Haznedaroglu IC. Time to take a healthier view of history. Nature 1998;396:108.
3. Bilgili H, Captug O, Kosar A, Kurt M, Kekilli M, Shorbagi A, Kurt OK, Ozdemir O, Goker H, Haznedaroglu I. Oral systemic administration of ankaferd blood stopper has no short-term toxicity in an in vivo rabbit experimental model. Clin Appl Thromb Hemost. 2010; 16: 533-536.
4. Bilgili H, Kosar A, Kurt M, Onal IK, Goker H, Captug O, Shorbagi A, Turgut M, Kekilli M, Kurt OK, Kirazli S, Aksu S, Haznedaroglu IC. Hemostatic efficacy of ankaferd blood stopper in a swine bleeding model. Med Principl Pract 2009;18:165-169.
5. Cipil H, Kosar A, Kaya A, Uz B, Haznedaroglu IC, Goker H, Ozdemir O, Koroglu M, Kirazli S, Firat H. In vivo hemostatic effect of the medicinal plant extract ankaferd blood stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost 2009;15:270-276.
6. Huri E, Akgul T, Ayyildiz A, Ustun H, Germiyanoglu C. Hemostatic role of a folkloric medicinal plant extract in a rat partial nephrectomy model: Controlled experimental trial. J Urol 2009;181:2349-2354.
7. Kosar A, Cipil HS, Kaya A, Uz B, Haznedaroglu IC, Goker H, Ozdemir O, Koroglu M, Kirazli S, Firat H. In vivo and in vitro hemostatic effect of the medicinal plant extract ankaferd blood stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost 2009;15:270-276.
8. Firat H, Ozdemir O, Kosar A, Goker H, Haznedaroglu I. Annual review of ankaferd 08-09. Istanbul, Naviga Scientific Publications, 2009: pp. 1-175.
9. Arslan S, Haznedaroglu IC, Oz B, Goker H. Endobronchial application of ankaferd blood stopper to control diffuse lung bleeding leading to hypoxemia and hemodynamic instability. Resp Med 2009;2:144-146.
10. Dogan OF, Ozyurda U, Uymaz OK, Ercetin S, Haznedaroglu I. New anticoagulant agent for CABG surgery. Eur J Clin Invest 2008;38:341.
11. Huri E, Akgul T, Ayyildiz A, Germiyanoglu C. Hemostasis in retropubic radical prostatectomy with ankaferd bloodstopper: A case report. Kaohsiung J Med Sci 2009;25:445-447.
12. Ibis M, Kurt M, Onal IK, Haznedaroglu IC. Successful management of bleeding due to solitary rectal ulcer via topical application of ankaferd blood stopper. J Altern Complement Med 2008;14:1073-1074.
13. Kurt M, Akdogan M, Onal IK, Kekilli M, Arhan M, Shorbagi A, Aksu S, Kurt OK, Haznedaroglu IC. Endoscopic topical application of ankaferd blood stopper for neoplastic gastrointestinal bleeding: A retrospective analysis. Dig Liver Dis 2010;42:196-199.
14. Kurt M, Disibeyaz S, Akdogan M, Sasmaz N, Aksu S, Haznedaroglu IC. Endoscopic application of ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: A case report. Am J Gastroenterol 2008;103:2156-2158.
15. Kurt M, Kacar S, Onal IK, Akdogan M, Haznedaroglu IC. Ankaferd blood stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract. Endoscopy 2008;40 Suppl 2:E262.
16. Öner AF, Doğan M, Kaya A, Sal E, Bektaş MS, Yesilmen O, Ayhan H, Acikgoz M. New coagulant agent (ankaferd blood stopper) for open hemorrhages in hemophilia with inhibitor. Clin Appl Thromb Hemost 2010;16:705-707.
17. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, Bilgili H, Goker H, Akman U, Ozturk Y, Firat HC. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of ankaferd blood stopper. Clin Appl Thromb Hemost 2010;16:446-453.
18. Akkoc N, Akceik M, Haznedaroglu I, Goker H, Aksu S, Kirazli S, Firat H. In vivo anti-bacterial activities of ankaferd blood stopper. Int J Lab Hematol 2008;30:95.
19. Tasdelen Fisgin N, Tanriverdi Cayci Y, Coban AY, Ozatli D, Tanyel E, Durupinar B, Tulek N. Antimicrobial activity of plant extract ankaferd blood stopper. Fitoterapia 2009;80:48-50.
20. Turhan N, Kurt M, Akdogan M, Haznedaroglu I. Topical ankaferd blood stopper administration to bleeding gastrointestinal carcinomas can decrease tumor vascularization. Am J Gastroenterol 2009;104:2874-2877.
21. Demiralp DO, Haznedaroglu IC, Akar N: Functional proteomics of ankaferd blood stopper. Turkish Journal of Hematology 2010;27: 70-77.
22. Aktas A, Er N, Onur MA: Effects of ankaferd blood stopper on vascular response in rat carotid artery. UHOD Int J Hematol Oncol. 2010; 20: 156-162.

23. Haznedaroglu IC. Molecular basis of the pleiotropic effects of ankaferd blood stopper. IUBMB Life 2009;61:290.

24. Yılmaz E, Gulec S, Haznedaroglu IC, Akar N: Effects of ankaferd on huve cell transcription factors and erythrocyte protein profile: Turkish Journal of Hematology 2011;28:276-285

25. Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13(5): 382-385.

26. Akar N, Gokdemir R, Ozel D, Akar E. Endothelial cell protein c receptor (EPCR) gene exon III, 23 bp insertion mutation in the turkish pediatric thrombotic patients. Thromb Haemost 2002; 88:1068-1069.

27. Eroğlu A, Ulu A, Kurtman C, Cam R, Akar N. 23-bp endothelial protein c receptor (EPCR) gene insertion mutation in cancer patients with and without thrombosis. Am J Hematol 2006;81:220.

28. Kendirli T, Ince E, Cifçi E, Dogru U, Egin Y, Akar N. Soluble endothelial protein c receptor level in children with sepsis. Pediatr Hematol Oncol 2009;26:432-438.

29. Orhon FS, Ergun H, Egin Y, Ulukol B, Baskan S, Akar N. Soluble endothelial cell protein C receptor levels in healthy population. J Thromb Thrombolysis 2010;29:46-51.

30. Ulu A, Gunal D, Tiras S, Egin Y, Deda G, Akar N. EPCR gene a3 haplotype and elevated soluble endothelial protein c receptor (sEPCR) levels in Turkish pediatric stroke patients. Thromb Res 2007;120:47-52.

31. Yalcindag FN, Batioglu F, Ozdemir O, Cansizoglu E, Egin Y, Akar N. Soluble endothelial protein c receptor levels in behcet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol 2008;246:1603-1608.

32. Sipahi T, Kara A, Kuybulu A, Egin Y, Akar N. Congenital Thrombotic Risk Factors in Beta-Thalassemia. Clin Appl Thromb Hemost 2009;15:581-584.

33. Yürürer D, Teber S, Deda G, Egin Y, Akar N. The Relation Between Cytokines, Soluble Endothelial Protein C Receptor, and Factor VIII Levels in Turkish Pediatric Stroke Patients. Clin Appl Thromb Hemost 2009;15:545-551.

34. Ozturk MA, Ertendi I, Kizil S, Haznedaroğlu, IC, Celik I, Kizil S, Calguneri M. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet’s disease. Rheumatol Int 2004;24:98-102.

35. Providence KM, Higgins PJ. PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. J Cell Physiol 2004;200:297-308.

36. Oguzulgen IK, Yilmaz E, Demirtas S, Erkekol FO, Ekim N, Demir N, Numanoglu N, Ozel D, Ulu A, Akar N. The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism. Clin Appl Thromb Hemost. 2009;15:73-77.

37. Stewart I, Schluter PJ, Shaw GR. Cyanobacterial lipopolysaccharides and human health - a review. Environ Health 2006; 5:7.

38. Turgut M, Tutkun F, Çelebi N, Muğlalı M, Goker H, Haznedaroğlu IC: Topical ankaferd bloodstopper in the management of critical bleedings due to hemorrhagic diathesis. UHOD Int J Hematol Oncol. 2011; 21:160-165.

39. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007;204:2439-2448.

40. Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML. Upa and PAI-1 in rectal cancer-relationship to radiotherapy and clinical outcome. J Surg Res 2009;153:46-53.

41. Fabre-Guillemin E, Malo M, Cartier-Michaud A, Peinado H, Moreno-Bueno G, Vallee B, Lawrence DA, Palacios J, Cano A, Barlovatz-Meimon G, Charriere-Bertrand C. PAI-1 and functional blockade of snai1 in breast cancer cell migration. Breast Cancer Res 2008;10:100.